(2E)-3-(1,3-苯并噻唑-2-基)丙烯酸 | 4123-18-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 中文名称: (2E)-3-(1,3-苯并噻唑-2-基)丙烯酸
• 英文名称: 3-benzothiazol-2-yl-acrylic acid
• 英文别名: (2E)-3-(1,3-Benzothiazol-2-YL)prop-2-enoic acid；3-(1,3-benzothiazol-2-yl)prop-2-enoic acid
• CAS: 4123-18-6
• 化学式: C₁₀H₇NO₂S
• 分子量: 205.237
• InChiKey: LLWKVCNWFMPGGM-UHFFFAOYSA-N

物化性质

• 熔点：
  218-219 °C
• 沸点：
  410.3±47.0 °C(Predicted)
• 密度：
  1.446±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  78.4
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  (2E)-3-(1,3-苯并噻唑-2-基)丙烯酸 在 potassium permanganate 、 氯仿 、 potassium carbonate 作用下， 生成 苯并噻唑-2-甲醛
  参考文献：
  名称：

  613.一些三核花青染料。第五部分：尝试合成与新花青类异构体的染料

  摘要：

  DOI：

  10.1039/jr9520003197
• 作为产物：
  描述：

  2'-mercapto maleianilinic acid 在 硫酸 作用下， 反应 5.0h， 生成 (2E)-3-(1,3-苯并噻唑-2-基)丙烯酸
  参考文献：
  名称：

  Kassem, Emad M. M.; Michael, Josephine M.; El-Masry, A. H., Pakistan Journal of Scientific and Industrial Research, 1995, vol. 38, # 11-12, p. 424 - 427

  摘要：

  DOI：

文献信息

• Amido compounds as RORγt modulators and uses thereof
  申请人：Littman Dan

  公开号：US09765063B2

  公开（公告）日：2017-09-19

  Amido compounds are disclosed that have a formula represented by the following: and wherein Cy1, Cy2, n1, n2, R1a, R1b, R2, R3, R4, R5, and R6 are as described herein. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune disorders, cancer, and graft-versus-host disease.

  披露了具有以下公式表示的氨基化合物：其中Cy1、Cy2、n1、n2、R1a、R1b、R2、R3、R4、R5和R6如本文所述。这些化合物可以制备为药物组合物，并可用于预防和治疗哺乳动物，包括人类，的各种疾病，包括但不限于炎症性疾病、自身免疫疾病、癌症和移植物抗宿主病。
• Carbamic acid compounds comprising a bicyclic heteroaryl group as hdac inhibitors
  申请人：Finn W Paul

  公开号：US20060079528A1

  公开（公告）日：2006-04-13

  This invention pertains to certain carbamic acid compounds of the following formula, which inhibit HDAC (histone deacetylase) activity wherein: A is independently an unsubstituted or substituted bicyclic C 9-10 heteroaryl group (e.g., quinolinyl; quinoxalinyl; benzoxazolyl; benzothiazolyl); Q is an acid leader group, and is independently an unsubstituted or substituted, saturated or unsaturated C 17 alkylene group having a backbone length of 4 or less; with the proviso that if A is unsubstituted benzothiazol-2-yl, then Q is an unsaturated group; and with the proviso that if A is unsubstituted quinolin-6-yl, then Q is unsubstituted at the a-position; and with the proviso that A is not benzimidazol-2-yl; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit HDAC, and in the treatment of conditions mediated by HDAC, cancer, proliferative conditions, psoriasis, etc.

  本发明涉及以下公式的某些碳酰胺化合物，其抑制HDAC（组蛋白去乙酰化酶）活性，其中：A是独立的未取代或取代的双环C9-10杂环基团（例如，喹啉基；喹啉并咪唑基；苯并噁唑基；苯并噻唑基）；Q是酸性引导基团，且是独立的未取代或取代的饱和或不饱和C17烷基基团，其骨架长度不超过4；但前提是，如果A是未取代的苯并噻唑-2-基，则Q是不饱和基团；如果A是未取代的喹啉-6-基，则Q在α位未取代；A不能是苯并咪唑-2-基；以及其药学上可接受的盐，溶剂化合物，酰胺，酯，醚，化学保护形式和前药。本发明还涉及包含这些化合物的制药组合物，以及在体内外使用这些化合物和组合物来抑制HDAC并治疗由HDAC介导的疾病，如癌症，增殖性疾病，牛皮癣等。
• CARBAMIC ACID COMPOUNDS COMPRISING A BICYCLIC HETEROARYL GROUP AS HDAC INHIBITORS
  申请人：FINN Paul W.

  公开号：US20100093743A1

  公开（公告）日：2010-04-15

  This invention pertains to certain carbamic acid compounds of the following formula, which inhibit HDAC (histone deacetylase) activity wherein: A is independently an unsubstituted or substituted bicyclic C 9-10 heteroaryl group (e.g., quinolinyl; quinoxalinyl; benzoxazolyl; benzothiazolyl); Q is an acid leader group, and is independently an unsubstituted or substituted, saturated or unsaturated C 1 7 alkylene group having a backbone length of 4 or less; with the proviso that if A is unsubstituted benzothiazol-2-yl, then Q is an unsaturated group; and with the proviso that if A is unsubstituted quinolin-6-yl, then Q is unsubstituted at the α-position; and with the proviso that A is not benzimidazol-2-yl; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit HDAC, and in the treatment of conditions mediated by HDAC, cancer, proliferative conditions, psoriasis, etc.

  本发明涉及以下式的某些碳酰胺类化合物，其抑制HDAC（组蛋白去乙酰化酶）活性，其中：A是独立的未取代或取代的双环C9-10杂环基团（例如，喹啉基；喹啉氧基基；苯并噁唑基；苯并噻唑基）；Q是酸性引导基团，且是独立的未取代或取代的饱和或不饱和的C1 7烷基基团，其骨架长度为4或更短；但是，如果A是未取代的苯并噻唑-2-基，则Q是不饱和基团；如果A是未取代的喹啉-6-基，则Q在α-位置未取代；且A不是苯并咪唑-2-基；以及其药学上可接受的盐、溶剂化合物、酰胺、酯、醚、化学保护形式和前药。本发明还涉及包含这些化合物的制药组合物，以及这些化合物和组合物在体内外抑制HDAC和治疗由HDAC介导的疾病，如癌症、增殖性疾病、牛皮癣等方面的用途。
• Factor XIIIa inhibitor compounds useful for thrombolytic therapy
  申请人：MERCK & CO. INC.

  公开号：EP0294016A2

  公开（公告）日：1988-12-07

  Certain Factor XIIIa inhibitor compounds have been discovered which have been found to be useful in the lysis of blood clots and thus adaptable for administration in thrombolytic therapy either alone or together with plasminogen activator.

  现已发现某些因子 XIIIa 抑制剂化合物可用于溶解血凝块，因此可单独或与纤溶酶原激活剂一起用于溶栓治疗。
• Ried; Keller, Chemische Berichte, 1956, vol. 89, p. 2578,2582
  作者：Ried、Keller

  DOI：——

  日期：——